AJANTPHARM

Feb 10 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA LTD - ISSUES CLARIFICATION ON MEDIA REPORT

• AJANTA PHARMA LTD - DENIES PLANS TO BUY RESTAURANT BRANDS ASIA

Source text: ID:nBSE53rVT9

Further company coverage: AJPH.NS

(([email protected];))

Jan 20 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA LTD - HAS NOT CONSIDERED ACQUIRING STAKE IN RESTAURANT BRANDS ASIA

• AJANTA PHARMA LTD - REFERENCE TO AJANTA PHARMA IN NEWS ARTICLE IS INCORRECT

Source text: ID:nBSE2p127p

Further company coverage: AJPH.NS

(([email protected];;))

By Aditya Kalra, Yantoultra Ngui and Vibhuti Sharma

NEW DELHI/SINGAPORE, Jan 19 (Reuters) - Private equity firm Everstone will sell its entire 11.26% stake in Burger King's India and Indonesia franchisee Restaurant Brands Asia RESR.NS, as part of a deal to be announced on Tuesday, two people with direct knowledge of the matter said.

Everstone Capital's stake, through its investment vehicle QSR Asia Pte Ltd, is valued at $57 million currently, according to Refinitiv data. Restaurant Brands Asia has a market capitalisation of $437 million in Mumbai.

Under the deal, Restaurant Brands Asia will get a new strategic investor, said the two sources, who declined to be named as the matter is confidential.

Everstone and Restaurant Brands Asia did not respond to Reuters requests for comment.

The family office of the founders of India's Ajanta Pharma, which also runs other restaurant businesses, is set to be the strategic investor in the deal, and could inject up to 8 billion Indian rupees ($88 million) in the company, according to one of the sources.

Representatives of the family office did not respond to a request for comment.

It was not immediately clear what stake Ajanta would take in the company, but the source added it was considering taking up a majority stake in due course as other shareholders sell out.

Restaurant Brands Asia told Indian stock exchanges last week that it planned to hold a board meeting on Tuesday to "consider and evaluate raising of funds". It did not elaborate.

(Reporting by Aditya Kalra in New Delhi and Yantoultra Ngui in Singapore; Editing by Emelia Sithole-Matarise)

((Email: [email protected]; X: @adityakalra;))

** Ajanta Pharma AJPH.NS rises 2.5% to 2,757.30 rupees

** Motilal Oswal says AJPH's partnership with Biocon BION.NS to source weight-loss drug semaglutide is "meaningful step" towards introducing newer therapies, way for AJPH to secure market share

** Forecasts potential annualised sales from semaglutide in Asia and Africa at $25-30 mln from H2 FY28, EBITDA margin of 50-55%

** Expects AJPH's overall revenue and profit to grow at 11% and 16% CAGR, respectively, over FY26-28

** Reiterates "buy" rating on AJPH with PT of 3,145 rupees

** Avg rating of 13 analysts is "buy"; median PT is 3,120 rupees - data compiled by LSEG

** YTD, AJPH down 6% vs pharma index's .NIPHARM 3.9% decline

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Ajanta Pharma AJPH.NS rise 2.4% to 2,626.30 rupees

** Jefferies starts coverage on AJPH with 'buy' and price target of 2,850 rupees

** Brokerage expects AJPH to further improve its market positioning and achieve mid-teens revenue growth for branded generics segment

** Co expected to achieve 200 bps margin expansion to 29.5% on rising contribution from branded generic markets - Jefferies

** Brokerage sees limited impact from potential US reciprocal tariffs for AJPH margins as US margins are much lower than company avg

** Analysts, on average, rate AJPH at "buy", median PT is 2,990 rupees - data compiled by LSEG

** AJPH down ~10% in 2025 after gaining 40.7% in 2024

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS rise 4.15% to 2735.45 rupees

** Stock rises after the specialty pharmaceutical company announced its plans to expand manufacturing capabilities to meet growing global demand

** AJPH to add a liquid formulation facility at its Pithampur site in Madhya Pradesh

** Facility to boost capacity to 12 million bottles per annum, from the current 6 million bottles

** AJPH says the capacity expansion will require an investment of 920 million rupees ($10.66 million)

** AJPH shares are down 7.1% so far in 2025, against an 8% fall in the pharma index .NIPHARM, of which it is a constituent

($1 = 86.2650 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Jan 30 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• DEC-QUARTER CONSOL NET PROFIT 2.33 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.46 BILLION RUPEES

Source text: ID:nBSE7SQY1v

Further company coverage: AJPH.NS

(([email protected];;))

Oct 28 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA SEPT-QUARTER CONSOL NET PROFIT 2.16 BILLION RUPEES

• AJANTA PHARMA LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 11.87 BILLION RUPEES

• AJANTA PHARMA LTD - DIVIDEND 28 RUPEES PER SHARE

Source text: ID:nBSE2kT0DX

Further company coverage: AJPH.NS

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS climb as much as 6.7% to a record high of 2,579.90 rupees

** Stock set for ninth straight session of gain

** Drugmaker's Q1 consol profit after tax rose 18% Y/Y; rev grew 12% Y/Y

** Mean rating of nine analysts is "buy"; median PT is 2,400 rupees - LSEG data

** Stock up 24% YTD after gaining 73% in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Ajanta Pharma AJPH.NS rise as much as 13.7% to a record high of 2,540 rupees; last up 8.7%

** Stock is the top gainer in the Nifty 500 index .NIFTY500 and is on pace for its 11th consecutive session of gains

** The specialty pharmaceuticals maker reported a 65.8% jump in its consolidated profit for the quarter ended March 31 to 2.03 bln rupees ($24.4 mln)

** Revenue from operations rose 19.5% Y/Y

** Co has also approved a buy-back of equity shares at a price of 2,770 rupees per share

** Stock posts biggest intraday pct gain since Feb. 20, 2020

** Average rating of 10 analysts covering the stock is "buy"; median PT is 2,235 rupees - LSEG data

** More than 871,000 shares change hands as of 9:52 a.m. IST, 8.1x 30-day average

** Including session's gain, stock is up 17% YTD

($1 = 83.3790 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

May 2 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA LTD - APPROVAL OF BUY-BACK OF EQUITY SHARES

• AJANTA PHARMA LTD - APPROVAL OF BUY-BACK OF EQUITY SHARES AT PRICE 2770 RUPEES PER SHARE

• AJANTA PHARMA LTD - BUY-BACK UPTO 2.85 BILLION RUPEES

• AJANTA PHARMA MARCH-QUARTER CONSOL PROFIT 2.03 BILLION RUPEES VERSUS PROFIT 1.22 BILLION RUPEES

• AJANTA PHARMA LTD - BUY-BACK THROUGH TENDER OFFER

• AJANTA PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 10.54 BILLION RUPEES VERSUS 8.82 BILLION RUPEES

Source text for Eikon: ID:nBSE8VwH6V

Further company coverage: AJPH.NS

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS rise as much as 5.8% to 2,300 rupees in early trading; stock has since pared gains, now up 1.5%

** Pharma co reported a 56.1% Y/Y jump in third-quarter net profit on 13.7% increase in rev from ops

** Stock trading above its 100-day moving averages since March end

** Avg rating of 12 analysts close to equivalent of "buy;" median PT is 2,030 rupees - LSEG

** Stock on track for a fourth consecutive quarter of gains, if trend holds

(Reporting by Navamya Ganesh Acharya)

(([email protected]; +91 8805175330 ;))

Jan 31 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA DEC-QUARTER CONSOL NET PROFIT 2.10 BILLION RUPEES VERSUS PROFIT 1.35 BILLION RUPEES

• AJANTA PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.05 BILLION RUPEES VERSUS 9.72 BILLION RUPEES

• AJANTA PHARMA LTD - DIVIDEND OF 26 RUPEES PER SHARE

Source text for Eikon: [ID:]

Further company coverage: AJPH.NS

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS rise 2.4% to a record high of 1,995.95 rupees

** Stock trading above its 50-, 100-, and 200-day moving averages since Nov. 1

** More than 180,000 shares change hands by 3:06 p.m. IST, 1x the 30-day avg

** Eleven analysts rate stock "buy" or higher, one "hold" and "sell"; median PT is 2030 rupees - LSEG data

** Including day's gains so far, stock up ~64.1% so far this year

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Oct 31 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• SEPT-QUARTER CONSOL NET PROFIT 1.95 BILLION RUPEES VERSUS 1.57 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 10.28 BILLION RUPEES VERSUS 9.38 BILLION RUPEES

Further company coverage: AJPH.NS

(([email protected];))

** Shares of specialty pharmaceuticals maker Ajanta Pharma AJPH.NS up as much as 9.37% to a record high of 1697.95 rupees

** Co on track for second consecutive session of gains if trends hold

** AJPH reported a near 19% rise in consolidated profit after tax for the quarter ended June 30 to 2.08 billion rupees ($25.3 million)

** Co approved total dividend of 25 rupees per share, which includes special dividend of 15 rupees per share

** About 388,293 shares change hands as of 9:25 a.m. IST, vs 2.5x 30-day average of 157,708 shares

** Stock up 28.1% YTD as of last close

($1 = 82.1973 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

July 27 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA JUNE-QUARTER CONSOL PAT 2.08 BILLION RUPEES VERSUS 1.75 BILLION RUPEES

• AJANTA PHARMA LTD - INTERIM DIVIDEND 25 RUPEES PER SHARE

• AJANTA PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 10.21BLN RUPEES VERSUS 9.51 BILLION RUPEES

Source text for Eikon: ID:nBSE1Vcrdq

Further company coverage: AJPH.NS

(([email protected];))

** Shares of speciality pharmaceuticals maker Ajanta Pharma AJPH.NS rise as much as 4.49% to 1,528.55 rupees

** Co said its formulation facility at Dahej was inspected by the U.S. FDA from June 19-23, and the regulator did not issue any Form 483

** A Form FDA 483 is issued to a company's management at the conclusion of an inspection when an investigator(s) has observed conditions that in their judgment may constitute violations of the Food, Drug, and Cosmetic (FD&C) Act and other Acts or regulations

** Share price above 50-day, 100-day and 200-day exponential moving averages since May 16, suggesting bullish trend

** More than 81,000 shares change hands vs 30-day avg of 123,038 shares

** Twelve of 13 analysts covering the stock have a "buy" or "strong buy" rating, while one has "hold"; median PT is 1,520 rupees - Refinitiv data

** Ajanta stock up 20.7% YTD, as of last close

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

May 5 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA MARCH-QUARTER CONSOL PROFIT 1.22 BILLION RUPEES VERSUS 1.51 BILLION RUPEES

• AJANTA PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 8.82 BILLION RUPEES VERSUS 8.70 BILLION RUPEES

Source text for Eikon: ID:nBSEV7qs7

Further company coverage: AJPH.NS

(([email protected];))